TPST vs. ALRN, MRNS, CNTB, SPRO, CRVS, BYSI, LFVN, VACC, LPTX, and BRNS
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Aileron Therapeutics (ALRN), Marinus Pharmaceuticals (MRNS), Connect Biopharma (CNTB), Spero Therapeutics (SPRO), Corvus Pharmaceuticals (CRVS), BeyondSpring (BYSI), LifeVantage (LFVN), Vaccitech (VACC), Leap Therapeutics (LPTX), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical preparations" industry.
Tempest Therapeutics (NASDAQ:TPST) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Aileron Therapeutics shares are held by institutional investors. 3.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 5.6% of Aileron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Aileron Therapeutics had 12 more articles in the media than Tempest Therapeutics. MarketBeat recorded 13 mentions for Aileron Therapeutics and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 0.59 beat Aileron Therapeutics' score of 0.13 indicating that Tempest Therapeutics is being referred to more favorably in the media.
Tempest Therapeutics is trading at a lower price-to-earnings ratio than Aileron Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 590.61%. Aileron Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 414.91%. Given Tempest Therapeutics' higher probable upside, analysts clearly believe Tempest Therapeutics is more favorable than Aileron Therapeutics.
Tempest Therapeutics has a beta of -1.65, suggesting that its stock price is 265% less volatile than the S&P 500. Comparatively, Aileron Therapeutics has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500.
Aileron Therapeutics' return on equity of -130.32% beat Tempest Therapeutics' return on equity.
Aileron Therapeutics received 120 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 66.88% of users gave Aileron Therapeutics an outperform vote while only 63.89% of users gave Tempest Therapeutics an outperform vote.
Summary
Aileron Therapeutics beats Tempest Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
